Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Sponsor: LB Pharmaceuticals Inc.
Summary
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.
Official title: A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB 102 in the Treatment of Adult Patients With Acute Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
456
Start Date
2026-03-25
Completion Date
2027-10
Last Updated
2026-05-06
Healthy Volunteers
No
Conditions
Interventions
LB-102 (50 mg tablet)
LB-102 oral tablet given for six weeks
LB-102 (100 mg tablet)
LB-102 oral tablet given for six weeks
Placebo
Placebo tablet given orally for six weeks
Locations (13)
Pillar Clinical Research
Bentonville, Arkansas, United States
Pillar Clinical Research
Little Rock, Arkansas, United States
Woodland International Research Group
Little Rock, Arkansas, United States
ProScience Research Group
Culver City, California, United States
CenExel
Garden Grove, California, United States
Synergy San Diego
Lemon Grove, California, United States
Clinical Innovations, Inc.
Riverside, California, United States
Health Synergy Clinical Research
Boynton Beach, Florida, United States
Innovative Clinical Research
Miami Lakes, Florida, United States
Accelerated Clinical Trial
Snellville, Georgia, United States
Pillar Clinical Research
Chicago, Illinois, United States
Arch Clinical Trials
St Louis, Missouri, United States
Neuro-Behavioral Clinical Research
North Canton, Ohio, United States